Search Articles — Sudonull

Search Results

From other projects

Enspryng reduced the risk of relapses in MOGAD by 68%

https://ymaho.com/enspryng-reduced-the-risk-of-relapses-in-mogad-by-68

Genentech proved the efficacy of satralizumab in a rare autoimmune disease. The risk of attacks decreased by 68%, new lesions by 79%. Learn how the first targeted drug fills the niche of empirical therapy.

Trending Now